Biotech Values

[dugafish]

Really great work, and thank you for the early heads up. Question, did you assume 25K or 30K? It appears 30K, not that it would make a huge diff.

==============
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=92234861

I conservatively model an average selling price for ABBV’s 3-DAA regimen of $30K for a 12-week course of treatment (higher in the US, lower in the EU). This translates into $3B of annual HCV sales booked by ABBV in the US and EU at peak throughput.
==============